Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Appl Immunohistochem Mol Morphol. 2016 Nov-Dec;24(10):703–711. doi: 10.1097/PAI.0000000000000248

Table 5.

Comparison of recurrence score (RS) categories and the estimated risk using ER, PR, HER2 and Nottingham grade in the validation set

ORS>30 ORS (18–30) ORS<18 Total
Estimate RS-High 4 1 0 5
Estimate RS-Intermediate 3 19 13 35
Estimate RS-low 0 8 43 51
Total 7 28 56 91